Pulmatrix and Cipla announce first patient dosed in phase 2 trial evaluating pulmazole
Pulmatrix announced the first patient has been dosed in the Phase 2 trial evaluating Pulmazole, an inhaled iSPERSE formulation of the antifungal itraconazole in development for treatment of Allergic Bronchopulmonary Aspergillosis in patients with asthma. September 18, 2019